Nasal Polyps: Pathogenesis and Treatment Implications

Otolaryngologic Clinics of North America

Volumn 44, Issue 3, 2011, Pages 685-695

  DeMarcantonio, Michael A ^a   Han, Joseph K ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Allergy; Asthma; Polyp; Rhinosinusitis; Sinusitis; Unified airway

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYTOKINE; DOXYCYCLINE; INTERLEUKIN 5 ANTIBODY; MONTELUKAST; STAPHYLOCOCCUS ENTEROTOXIN; TRANSFORMING GROWTH FACTOR BETA1; ZILEUTON;

ASPIRIN EXACERBATED RESPIRATORY DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CYSTIC FIBROSIS; DIAGNOSTIC IMAGING; DRUG MECHANISM; ENDOSCOPIC SINUS SURGERY; EOSINOPHILIA; HUMAN; NOSE POLYP; PATHOGENESIS; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; RHINOSINUSITIS; SYMPTOM; T LYMPHOCYTE;

ASTHMA, ASPIRIN-INDUCED; CHRONIC DISEASE; CYSTIC FIBROSIS; CYTOKINES; ENTEROTOXINS; EOSINOPHILIA; HUMANS; NASAL POLYPS; RHINITIS; SINUSITIS; STAPHYLOCOCCUS AUREUS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79957503287     PISSN: 00306665     EISSN: 15578259     Source Type: Journal    
DOI: 10.1016/j.otc.2011.03.005     Document Type: Review

References (64)

1. Larsen K., Tos M. The estimated incidence of symptomatic nasal polyps. Acta Otolaryngol 2002, 122(2):179-182.
2. Videler W.J., Van Drunen C.M., Van Der Meulen F.W., et al. Radical surgery: effect on quality of life and pain in chronic rhinosinusitis. Otolaryngol Head Neck Surg 2007, 136:261-267.
3. Van Zele T., Claeys S., Gevaert P., et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006, 61(11):1280-1289.
4. Bachert C., Wagenmann M., Hauser U., et al. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997, 99(6 Pt 1):837-842.
5. Johansson L., Akerlund A., Holmberg K., et al. Evaluation of methods for endoscopic staging of nasal polyposis. Acta Otolaryngol 2000, 120(1):72-76.
6. Lund V.J., Mackay I.S. Staging in rhinosinusitis. Rhinology 1993, 31:183-184.
7. Lildholdt T., Rundcrantz H., Bende M., et al. Glucocorticoid treatment for nasal polyps. The use of topical budesonide powder, intramuscular betamethasone, and surgical treatment. Arch Otolaryngol Head Neck Surg 1997, 123(6):595-600.
8. Drutman J., Harnsberger H.R., Babbel R.W., et al. Sinonasal polyposis: investigation by direct coronal CT. Neuroradiology 1994, 36(6):469-472.
9. Kaliner M.A., Osguthorpe J.D., Fireman P., et al. Sinusitis: bench to bedside. Current findings, future directions. Otolaryngol Head Neck Surg 1997, 116:S1-S5.
10. Fokkens W., Lund V., Mullol J. European position paper on rhinosinusitis and nasal polyps 2007, 20:1-136.
11. Chan Y., Kuhn F.A. An update on the classifications, diagnosis, and treatment of rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2009, 17(3):204-208.
12. Dykewicz M.S., Hamilos D.L. Rhinitis and sinusitis. J Allergy Clin Immunol 2010, 125(2 Suppl 2):S103-S115.
13. Pawanker R. Nasal polyposis: an update. Curr Opin Allergy Immunol 2003, 3:1-6.
14. Hellquist H.B. Nasal polyps update. Histopathology. Allergy Asthma Proc 1996, 17:237-242.
15. Venge P., Bystrom J., Carlson M., et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999, 29:1172-1186.
16. Sanderson C.J. Interleukin-5, eosinophils and disease. Blood 1992, 19:3101-3109.
17. Nakajima H., Takatsu K. Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 2007, 142(4):265-273.
18. Ochiai K., Kagami M., Matsumura R., et al. IL-5 but not interferon-gamma (IFN-gamma) inhibits eosinophil apoptosis by up-regulation of bcl-2 expression. Clin Exp Immunol 1997, 107(1):198-204.
19. Otto B.A., Wenzel S.E. The role of cytokines in chronic rhinosinusitis with nasal polyps. Curr Opin Otolaryngol Head Neck Surg 2008, 16(3):270-274.
20. Chen Y.S., Arab S.F., Westhofen M., et al. Expression of interleukin-5, interleukin-8, and interleukin-10 mRNA in the osteomeatal complex in nasal polyposis. Am J Rhinol 2005, 19(2):117-123.
21. Sakaguchi S., Miyara M., Costantino C.M., et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10(7):490-500.
22. Van Bruaene N., Pérez-Novo C.A., Basinski T.M., et al. T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol 2008, 121(6):1435-1441. 1441.e1-3.
23. Wang Q.P. Myofibroblasts accumulation induced by transforming growth factor-beta is involved in pathogenesis of nasal polyps. Laryngoscope 1997, 107:926-931.
24. Early S.B., Hise K., Han J.K., et al. Hypoxic induction stimulates inflammatory and fibrotic response from nasal-polyp derived fibroblasts. Laryngoscope 2007, 117(3):511-515.
25. Bradley D.T., Kountakis S.E. Role of interleukins and transforming growth factor-beta in chronic rhinosinusitis and nasal polyposis. Laryngoscope 2005, 115(4):684-686.
26. Little S.C., Early S.B., Woodard C.R., et al. Dual action of TGF-beta1 on nasal-polyp derived fibroblasts. Laryngoscope 2008, 118(2):320-324.
27. Early S.B., Han J.K., Borish L., et al. Histologic examination reveals distinct disease subsets of chronic sinusitis. J Allergy Clin Immunol 2007, 119(1):S243.
28. Payne S., Han J.K., Borish L., et al. Microarray analysis of distinct gene transcription profiles in non-eosinophilic chronic sinusitis with polyps. Am J Rhinol 2008, 22(6):568-581.
29. Kim J.W., Hong S.L., Kim Y.K., et al. Histological and immunological features of non-eosinophilic nasal polyps. Otolaryngol Head Neck Surg 2007, 137(6):925-930.
30. Zhang N., Van Zele T., Perez-Novo C., et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol 2008, 122(5):961-968.
31. Chen Z., O'Shea J.J. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008, 41(2):87-102.
32. Balaban N., Rasooly A. Staphylococcal enterotoxins. Int J Food Microbiol 2000, 61:1-103.
33. Patou J., Van Zel T., Fevaert P., et al. Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps. J Allergy Clin Immunol 2008, 121(1):110-115.
34. Van Zele T., Gevaert P., Watelet J.B., et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol 2004, 114(4):981-983.
35. Bachert C., Zhang N., Holtappels G., et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol 2010, 126(5):962-968. e1-6.
36. Stevenson D.D. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep 2009, 9(2):155-163.
37. de Alarcon A., Caughey R., Steinke J.W., et al. Overexpression of leukotriene c4 synthase and plasminogen activator inhibitor 1 gene promoter polymorphisms in sinusitis. Am J Rhinol 2006, 16(10):545-549.
38. Mullol J., Fernàndez-Morata J.C., Roca-Ferrer J., et al. Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps. J Allergy Clin Immunol 2002, 109(5):824-830.
39. Sestini P., Armetti L., Gambaro G., et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996, 153(2):572-575.
40. Robertson J.M., Friedman E.M., Rubin B.K. Nasal and sinus disease in cystic fibrosis. Paediatr Respir Rev 2008, 9(3):213-219.
41. Laurans M., Arion A., Fines-Guyon M., et al. Arch Pediatr 2006, 13(Suppl 1):S22-S29. [in French].
42. Claeys S., Van Hoecke H., Holtappels G., et al. Nasal polyps in patients with and without cystic fibrosis: a differentiation by innate markers and inflammatory mediators. Clin Exp Allergy 2005, 35(4):467-472.
43. Kim J.S., Hackley G.H., Okamoto K. Sputum processing for evaluation of inflammatory mediators. Pediatr Pulmonol 2001, 32:152-158.
44. Raoust E., Balloy V., Garcia-Verdugo I., et al. Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-dependent signaling in murine alveolar macrophages and airway epithelial cells. PLoS One 2009, 4(10):e7259.
45. Laube D.M., Yim S., Ryan L.K., et al. Antimicrobial peptides in the airway. Curr Top Microbiol Immunol 2006, 306:153-182.
46. Muhlebach M.S., Stewart P.W., Leigh M.W., et al. Quantification of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999, 160(1):186-191.
47. Mullol J., Obando A., Pujols L., et al. Corticosteroid treatment in chronic rhinosinusitis: the possibilities and the limits. Immunol Allergy Clin North Am 2009, 29(4):657-668.
48. Pujols L., Mullol J., Torrego A., et al. Glucocorticoid receptors in human airways. Allergy 2004, 59(10):1042-1052.
49. Rowe-Jones J.M., Medcalf M., Durham S.R., et al. Functional endoscopic sinus surgery: 5 year follow up and results of a prospective, randomised, stratified, double-blind, placebo controlled study of postoperative fluticasone propionate aqueous nasal spray. Rhinology 2005, 43(1):2-10.
50. Parnes S.M. The role of leukotriene inhibitors in patients with paranasal sinus disease. Curr Opin Otolaryngol Head Neck Surg 2003, 11:184-191.
51. Ragab S., Parikh A., Darby Y.C., et al. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001, 31(9):1385-1391.
52. Ulualp S.O., Sterman B.M., Toohill R.J. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J 1999, 78(8):604-606. 608, 613, passim.
53. Krouse J.H., Brown R.W., Fineman S.J., et al. Executive summary: asthma and the unified airway. Otolaryngol Head Neck Surg 2007, 136(Suppl 5):669-706.
54. Parameswaran N., Pizzichini M., Kjarsgaard M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360(10):985-993.
55. Gevaert P., Lang-Loidolt D., Lackner A., et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006, 118:1133-1141.
56. Huvenne W., van Bruaene N., Zhang N., et al. Chronic rhinosinusitis with and without nasal polyps: what is the difference?. Curr Allergy Asthma Rep 2009, 9(3):213-220.
57. Dufour X., Bedier A., Ferrie J.C., et al. Diffuse nasal polyposis and endonasal endoscopic surgery: long-term results, a 65-case study. Laryngoscope 2004, 114(11):1982-1987.
58. Proimos E., Papadakis C.E., Chimona T.S., et al. The effect of functional endoscopic sinus surgery on patients with asthma and CRS with nasal polyps. Rhinology 2010, 48(3):331-338.
59. Katotomichelakis M., Riga M., Davris S., et al. Allergic rhinitis and aspirin-exacerbated respiratory disease as predictors of the olfactory outcome after endoscopic sinus surgery. Am J Rhinol Allergy 2009, 23(3):348-353.
60. Albritton F.D., Kingdom T.T. Endoscopic sinus surgery in patients with cystic fibrosis: an analysis of complications. Am J Rhinol 2000, 14(6):379-385.
61. Schulte D.L., Kasperbauer J.L. Safety of paranasal sinus surgery in patients with cystic fibrosis. Laryngoscope 1998, 108(12):1813-1815.
62. Becker S.S., Han J.K., Gross C.W. Risk factors for recurrent sinus surgery in cystic fibrosis: review of a decade of experience. Am J Rhinol 2007, 21(4):478-482.
63. King V.V. Upper respiratory disease, sinusitis, and polyposis. Clin Rev Allergy 1991, 9:143-157.
64. Jarrett W., Militsakh O., Anstad M., et al. Endoscopic sinus surgery in cystic fibrosis: effects on pulmonary function and ideal body weight. Ear Nose Throat J 2004, 83:118-121.